237 related articles for article (PubMed ID: 26209736)
1. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.
Rudnicki M; Beckers A; Neuwirt H; Vandesompele J
Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv35-42. PubMed ID: 26209736
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.
Gholaminejad A; Abdul Tehrani H; Gholami Fesharaki M
J Nephrol; 2018 Dec; 31(6):813-831. PubMed ID: 30019103
[TBL] [Abstract][Full Text] [Related]
4. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.
Delić D; Eisele C; Schmid R; Baum P; Wiech F; Gerl M; Zimdahl H; Pullen SS; Urquhart R
PLoS One; 2016; 11(3):e0150154. PubMed ID: 26930277
[TBL] [Abstract][Full Text] [Related]
5. Renal microRNA- and RNA-profiles in progressive chronic kidney disease.
Rudnicki M; Perco P; D Haene B; Leierer J; Heinzel A; Mühlberger I; Schweibert N; Sunzenauer J; Regele H; Kronbichler A; Mestdagh P; Vandesompele J; Mayer B; Mayer G
Eur J Clin Invest; 2016 Mar; 46(3):213-26. PubMed ID: 26707063
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
Dewanjee S; Bhattacharjee N
Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.
Zanchi C; Macconi D; Trionfini P; Tomasoni S; Rottoli D; Locatelli M; Rudnicki M; Vandesompele J; Mestdagh P; Remuzzi G; Benigni A; Zoja C
Diabetologia; 2017 Jun; 60(6):1114-1125. PubMed ID: 28364255
[TBL] [Abstract][Full Text] [Related]
8. TRAIL and EGFR Pathways Targeting microRNAs are Predominantly Regulated in Human Diabetic Nephropathy.
Rai B; Pande A; Tiwari S
Microrna; 2023; 12(2):143-155. PubMed ID: 37098997
[TBL] [Abstract][Full Text] [Related]
9. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
Kölling M; Kaucsar T; Schauerte C; Hübner A; Dettling A; Park JK; Busch M; Wulff X; Meier M; Scherf K; Bukosza N; Szénási G; Godó M; Sharma A; Heuser M; Hamar P; Bang C; Haller H; Thum T; Lorenzen JM
Mol Ther; 2017 Jan; 25(1):165-180. PubMed ID: 28129112
[TBL] [Abstract][Full Text] [Related]
11. Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease.
Liu Y; Li H; Liu J; Han P; Li X; Bai H; Zhang C; Sun X; Teng Y; Zhang Y; Yuan X; Chu Y; Zhao B
J Am Soc Nephrol; 2017 Dec; 28(12):3627-3638. PubMed ID: 28923913
[TBL] [Abstract][Full Text] [Related]
12. Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Kang WL; Xu GS
Sci Rep; 2016 Jan; 6():19979. PubMed ID: 26813039
[TBL] [Abstract][Full Text] [Related]
13. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis.
Eissa S; Matboli M; Bekhet MM
Biomed Pharmacother; 2016 Oct; 83():92-99. PubMed ID: 27470555
[TBL] [Abstract][Full Text] [Related]
14. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
McClelland AD; Herman-Edelstein M; Komers R; Jha JC; Winbanks CE; Hagiwara S; Gregorevic P; Kantharidis P; Cooper ME
Clin Sci (Lond); 2015 Dec; 129(12):1237-49. PubMed ID: 26415649
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes.
Roux M; Perret C; Feigerlova E; Mohand Oumoussa B; Saulnier PJ; Proust C; Trégouët DA; Hadjadj S
Nephrol Dial Transplant; 2018 Dec; 33(12):2201-2207. PubMed ID: 29361146
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
Kato M; Natarajan R
Ann N Y Acad Sci; 2015 Sep; 1353(1):72-88. PubMed ID: 25877817
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy.
Zhou Z; Wan J; Hou X; Geng J; Li X; Bai X
Cell Death Dis; 2017 Mar; 8(3):e2658. PubMed ID: 28277542
[TBL] [Abstract][Full Text] [Related]
18. Identification of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis.
Tang S; Wang X; Deng T; Ge H; Xiao X
Sci Rep; 2020 Aug; 10(1):13468. PubMed ID: 32778679
[TBL] [Abstract][Full Text] [Related]
19. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs.
Sankrityayan H; Kulkarni YA; Gaikwad AB
Pharmacol Res; 2019 Mar; 141():574-585. PubMed ID: 30695734
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy.
Duan LJ; Ding M; Hou LJ; Cui YT; Li CJ; Yu DM
Biochem Biophys Res Commun; 2017 Mar; 484(3):598-604. PubMed ID: 28137588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
